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Abstract: Here, we investigated the influence of physicochemical characteristics of 
chondroitin sulfate (CS) on its in vitro absorption and anti-inflammatory activity. We 
used eight different synthetic and natural CS samples with a range of molecular weights 
(7-35 kDa) and sulfation patterns. Our studies indicate that the absorption of CS is 
moderately correlated to percentage of chondroitin-6-sulfate while the anti-inflammatory 
activity may be weakly related to the molecular weight and the amount of total sulfation 
in the samples. Our in vitro studies could provide helpful screening tools for quick and 
effective evaluation of CS samples as a preliminary step towards in vivo studies.  
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Introduction: Osteoarthritis (OA) is a growing health concern in the United States. It is 
estimated that at least 67 million people will suffer from physician-diagnosed arthritis by 
2030 (Issa & Sharma, 2006; Peat, McCarney, & Croft, 2001). Symptomatic therapies, 
employing non-steroidal anti-inflammatory drugs (NSAIDs), have been reported to be 
ineffective with questionable efficacy and adverse effects in many OA patients (Dieppe, 
1978). The high price of other such pharmacological interventions as cyclooxygenase-2 
(COX-2) inhibitors and local intra-articular steroid injections has outweighed their 
effectiveness or reduced side effects. In the recent past, nutritional supplements 
containing glucosamine and chondroitin sulfate (CS) have received much attention and 
support from researchers due to their promising potential in reducing pain and 
preserving joint functionality in patients with OA (McAlindon, LaValley, Gulin, & Felson, 
2000). Numerous clinical studies provided evidence suggesting that orally administered 
CS acts as a slow acting symptomatic drug in patients with OA and is safe at doses as 
high as 800 – 1200 mg/day (Bucsi & Poor, 1998; Uebelhart, Thonar, Delmas, 
Chantraine, & Vignon, 1998). CS consists of a heterogeneous group of compounds with 
variable molecular weights and sulfation patterns (N. Volpi 2004). The animal-extracted 
CS samples, often found in many common supplements, are known to exhibit a variety 
of molecular weights and chondroitin-4-sulfate (CS4) to chondroitin-6-sulfate (CS6) ratio 
(N. Volpi, 2004).  For instance, while CS samples extracted from porcine trachea exhibit 
a usual molecular weight ~18 kDa with a CS4-to-CS6 ratio of 2.4, shark cartilage 
derived CS samples possess >50 kDa molecular weight with a low CS4-to-CS6 ratio of 
0.47. Despite the potential of CS in treating OA, very little is known regarding the 
influence of aforementioned heterogeneity and sulfation patterns on the bioavailability, 
anti-inflammatory activity, and in general overall efficacy of CS based supplements. 
Indeed, the heterogeneities in CS are crucial for some of their functions and have been 
found to strongly impact the role of CS in neuronal regeneration, plasticity, and recovery 
(V. P. Swarup et al. 2013). Therefore, a detailed study exploring the effects of 
heterogeneities in CS on its adsorption, anti-inflammatory, and anti-oxidative properties 
is necessary for identifying, designing, and developing new CS structures that could be 
biochemically synthesized. Although some speculations have been made regarding the 
correlation between molecular weight of CS and their bioavailability, at present, no such 
targeted studies have been conducted either in vitro or in vivo.  
In this article, we investigated the influence of physicochemical characteristics of CS on 
its in vitro absorption and anti-inflammatory activity. We used eight different synthetic 
and natural CS samples with a range of molecular weights (7-35 kDa) and sulfation 
patterns. We employed Caco-2 monolayer cells to study the in vitro absorption and 
determine the permeability coefficients (Peff) of different CS samples. Furthermore, the 
anti-inflammatory activity of CS samples was assessed by their ability to inhibit 
expression of a panel of inflammatory cytokines- tumor necrosis factor-alpha (TNF-α), 
and interleukin-6 (IL-6). Of the eight CS samples evaluated, four had a Peff value of 15 x 
10-6 cm sec-1 or higher indicating moderate to high absorption. Two of the four samples 
with higher Peff values were high molecular weight compounds (~ 35 kDa) suggesting 
possible influence of molecular weight on the bioavailability of CS. All the CS samples 
significantly inhibited expression of TNF-α  (at both low ~5 mg/ml and high ~15 mg/ml 
concentrations) while the expression of IL-6 was inhibited by some of the CS samples at 
high concentration. Interestingly, we observed a moderate correlation between the 
absorption and percentage of 6-sulfated disaccharides in the CS samples while no 
correlation seemed to exist between the molecular weights and anti-inflammatory 
activity of these samples. 
 
Experimental: We obtained 8 different CS samples labeled from A-F (4 synthetic, 3 
bovine trachea-derives, 1 porcine trachea-derived) from Pharmavite, LLC, Northridge, 
CA (see Table 1). The physico-chemical characteristics of our samples including MW, 
CS4 and CS6 content were quantified using high performance size exclusion 
chromatography (HPSEC), enzymatic hydrolysis, and ion-pairing reversed-phase liquid 
chromatography.  
High performance size exclusion chromatography: For HPSEC, two Agilent Bio SEC-3 
(150 x 7.8 mm) columns with pore sizes 150 Å and 100 Å (Agilent, Part # 5190-2507 
and # 5190-2502) were connected in tandem.  80% buffer (30 mM Disodium hydrogen 
phosphate, 30 mM Sodium sulfate, pH ~7) and 20% ethanol was used as mobile phase 
at a flow rate of 1.0 ml/min and run time of 15 minutes. 5 µl injection volumes of 
standards or samples were injected and chromatograms were recorded at 205 nm using 
a photo diode array (PDA) detector (Waters # 2998 PDA detector). A standard curve 
was plotted using retention times of standards and their corresponding molecular 
weights. The standard curve was then used to determine molecular weights of CS 
samples whose retention times were known (see Table 1).  Briefly, CS samples were 
incubated with chondroitinase AC II, an enzyme specific to chondroitin sulfate for 3 
hours at 37 oC to hydrolyze CS into its component disaccharides. Disaccharides were 
then separated and quantified by ion-pairing liquid chromatography with ultraviolet 
detection at 240 nm. While tetrabutylammonium bisulfate (340 mg; Sigma, Catalog # 
86868) was dissolved in 1L of water (HPLC grade) for mobile phase A, 340 mg of 
tetrabutylammonium bisulfate was dissolved in 330 ml water and 670 ml acetonitrile 
(HPLC grade) for obtaining mobile phase B. Tris- (hydroxymethyl) aminomethane 
(TRIS) buffer solution was prepared by dissolving 3 g of TRIS (Sigma, Catalog # 
T1503), 2.4 g of anhydrous sodium acetate (Sigma, Catalog # S8750), 1.46 g of sodium 
chloride (ACS reagent grade), and 50 mg crystalline bovine serum albumin (Sigma, 
Catalog # A4378) in 100 ml of 0.12 M HCl. The pH of TRIS buffer was adjusted to 7.3 
by adding adequate amount of 6M HCl (HPLC grade). 
Enzymatic hydrolysis: For enzymantic hydrolysis, 5 units of chondroitinase AC II 
enzyme (Seikagaku America, Catalog # 100335-1A) were dissolved in 0.5 ml water and 
the stored at < 0 oC when not in use. CS disaccharide reference standards (non-
sulfated, CS4, and CS6 samples) were purchased from Sigma (Catalog # C3920, 
C4045 and C4170 respectively). The standard CS stock solutions were prepared by 
dissolving 2 mg of non-sulfated or 10 mg of CS4/CS6 each in 50 ml of water. A serial 
dilution of the stock solution was performed to obtain standard disaccharide solutions 
with concentrations of CS4 and CS6 between 2 - 100 µg/ml and non-sulfated samples 
between 0.4 - 20 µg/ml. Twenty µl of TRIS buffer solution, 30 µl of enzyme solution and 
20 µl of CS sample were pipetted into 0.5 ml eppendorf tubes for enzymatic hydrolysis. 
The Eppendorf tubes were then incubated in a water bath at 37 oC for 3 hours. Once 
removed from water bath, the samples in eppendorf tubes were allowed to cool to room 
temperature. 230 µl of mobile phase A was added to the tubes and the hydrolyzed CS 
solution was transferred into 2 ml HPLC vials. The eppendorf tubes were rinsed with 
another 200 µl of mobile phase A, which was transferred into the HPLC vial with 
hydrolyzed CS solution. Another 500 µl of mobile phase A was added to those vials and 
mixed well. Waters HPLC machine connected to a PDA detector (Waters, Part # 2996) 
was used to analyze the CS disaccharide standards and CS samples. Phenomenex 
SynergiTM Polar-RP, 4.6 x 150 mm, 4 µm column was equilibrated with 80 % mobile 
phase A and 20% mobile phase B. 
In-vitro absorption studies: We obtained ADMEcell CacoReady™ Caco-2 cell kits for in 
vitro intestinal absorption evaluation. This kit provided a 21-cell barrier in integrated 
HTS Transwell® -24 (Corning Lifesciences) with a proprietary shipping medium that is 
stable at room temperature. The kit of differentiated Caco-2 cell barriers was shipped on 
13th day of differentiation and provided 14- day polarized cultures of Caco-2 cells on 
polycarbonate micro-porous filters in HTS Transwell® -24 plates (6.5 mm diameter, 0.33 
cm2 area and 0.4 µm pore diameter). For Caco-2 medium, 50 ml of fetal bovine serum 
(FBS) (Invitrogen, Catalog # 26140), 5 ml of 200 mM L-glutamine (Invitrogen, Catalog # 
25030) and 5 ml of Penicillin/Streptomycin (Invitrogen, Catalog # 15150-148) were 
added to 440 ml of Dulbecco’s modified eagle medium (DMEM) (Invitrogen, Catalog # 
10567).Final concentrations of 30 mg/ml CS working samples were prepared by 
dissolving 150 mg of each CS sample in 50 ml sterile 1 X Hank’s balanced salt solution 
(HBSS) transport buffer. HBSS transport buffer had a composition of 1 X Hank’s 
balanced salt solution (HBSS) (Lonza, Catalog #b04-315Q) with 1.1 mM MgCl2. 6H2O 
(Amresco, Catalog # E525) and 1.3 M CaCl2. 2H2O (Amresco, Catalog # E506). Since 
CS is water soluble, all the CS samples dissolved completely in transport buffer. The 
samples were then aliquoted and stored at 2-8 oC until the day of permeability study. 
We used 0 µM – 20 µM propranolol hydrochloride solutions high permeability control 
and sodium Fluorescein (Sigma, Catalog # 46960) as a low permeability control. A 200 
µM Lucifer yellow CH dilithium salt (Sigma, Catalog # L0259) solution was prepared and 
was used to test integrity of the Caco-2 cell monolayer. 
On the day of permeability experiments, transepithelial electrical resistance (TEER) 
measurement was performed using an Epithelial Volt-Ohm meter (EVOM) (World 
precision instruments, Catalog # EVOM2) on the CacoReady™ plate prior to any further 
processing. Any monolayers with TEER > 1000 Ohm. cm2 were considered acceptable 
for permeability assays. The CS samples, blank transport buffer, high permeability and 
low permeability controls, and Lucifer yellow were all warmed to 37 oC prior to the 
experiments. The basal compartment of CacoReady™ plate was washed with 750 ul of 
transfer buffer per well. Following aspiration of the transport buffer wash, 750 µl of 
transport buffer was aliquoted per well again. Cell culture medium from apical 
compartment wells was aspirated, discarded, and the apical wells were gently washed 
using 300 µl of transport buffer per well. Subsequently, 300 µl of CS samples, controls 
and blank transport buffer were filled in the apical wells. CacoReady™ plate with 
samples was placed in the incubator at 37 oC, 5% CO2 for 2 hours. After 2 hrs, samples 
from apical wells and basal wells of the CacoReady™ plate were then collected 
separately into 1 ml Eppendorf tubes. Quantitative analysis of CS in apical and basal 
samples was done by enzyme hydrolysis and liquid chromatography. Apical and basal 
concentrations of propranolol, sodium fluorescein and lucifer yellow were analyzed by 
Fluorescence spectrophotometry (SpectraMax M2e, Molecular Devices, LLC., 
Sunnyvale, CA). 
Inflammatory response: The influence of CS on the production of inflammatory markers 
such as TNF-α (Invitrogen, Catalog # 3012), IL-1β, IL-6, and NO production (Griess 
reagent) was measured on RAW264.7 cells using standard ELISA and Griess reagent 
kits.  
 
Results and Discussion: As shown in Table 1, the molecular weights of sample A-F, 
obtained using HPSEC, were found to range from 7-35 KDa. Considering the limited 
sensitivity of the HPSEC in separating samples very close to each other in size, it was 
difficult to obtain the absolute molecular weights of these samples. Nonetheless, it could 
be gleaned from Table 1 that the sample pairs A-B, C-D, E-F, and G-H possess similar 
molecular weights. Although the samples differed from each other in % ΔDi-6S, they do 
not differ much in total sulfation (= % ΔDi-4s+% ΔDi-6S). Importantly, samples B, G and 
H had higher % ΔDi-6S compared to the other CS samples used in this study.  
Considering its morphological and functional similarities to the enterocytes of small 
intestine, Caco-2 has been used as a well-established in vitro method for evaluating 
drug/nutrient absorption. Although the bioavailability of a drug is hard to be quantified 
using Caco-2 studies, it is still helpful to qualitatively rank a series of compounds (in this 
case, samples A-F) in order of their possible absorbability.  
Any compounds with Peff values over 10-6 cm s-1 are considered to be of high absorption 
with over 90% absorption while compounds with Peff < 10-7 cm s-1 have a very low 
absorption (Artursson et al., 2001).  
As shown in Fig. 1a, Sample B exhibited the highest Peff among the samples. Although 
samples A and B were of similar molecular weight, their Peff values were found to 
different with Peff for B > Peff for A. Such an observation may possibly be attributed to 
the fact that % ΔDi- 6S in sample B is higher to sample A. Despite of their comparatively 
higher molecular weights, samples G and H showed higher absorption than the lower 
molecular weight samples A, C, D and E and whose % ΔDi- 6S was lower than that of 
samples G and H. Fig. 1b showed that no correlation exists between molecular weight 
and Peff suggesting that the absorption of CS is independent of molecular weight. The 
bivariate fit of Peff and % ΔDi- 6S in CS sample resulted in R-square value of 0.5 (weak 
correlation) and a p-value ~0.0477 revealing that CS absorption may depended upon % 
ΔDi- 6S  and alternatively the source material of CS. (Fig. 1c). Such an observation may 
possibly explain the earlier results wherein shark chondroitin sulfate exhibited a higher 
absorption despite its high molecular weight of 44 kDa seen in humans (N. Volpi, 2003). 
A lack of natural or synthetic CS samples with pure ΔDi-4S in our sample set, no 
correlation data could be obtained for Peff and % ΔDi-4S. Nonetheless, the significant 
effect of % ΔDi-6S on Peff (Fig. 1c) combined with a lack of correlation between % total 
sulfated ΔDi and Peff (Fig. 1d) indicates that the presence of non-zero amounts of 4S 
may negate positive correlation of ΔDi-6S with Peff in CS.  
 
We observed that all CS samples exhibited moderate to strong anti-inflammatory 
activity by inhibiting inflammatory cytokine (TNF-α and IL-6) production by the RAW 
264.7 cells. Our results are in agreement with cytokine lowering effect of CS as reported 
by several researchers in in vitro studies (G. M. Campo et al., 2009), animal (Bauerova 
et al., 2011; Giuseppe M. Campo et al., 2003) studies. As shown in Table 2 and Fig. 2, 
the % reduction in TNF-α may be very weakly correlated to MW and % ΔDi-total since it 
exhibited R2 values > 0.42. Furthermore, it is possible that % reduction in TNF-α is 
related to % ΔDi-4S since no (weak) correlation existed between TNF-α and % ΔDi-6S 
(% ΔDi-total). Interestingly, the correlation between TNF-α and MW/% ΔDi-total were 
found to be more pronounced at higher CS concentrations (15 µg/ml). We did not find 
any systematic correlations had been observed between the molecular weights, % ΔDi-
6S or total % sulfated ΔDi and IL-6 levels. At 5 µg/ml concentration, sample B ranked 
high among the samples in inhibiting the production of LPS stimulated TNF-α in RAW 
264.7 cells. However, at the same concentration, the inhibition of IL-6 by sample B was 
not significant compared to LPS positive. At 15 µg/ml concentration, sample B stands 
out as the best among the CS samples by inhibiting production of both TNF-α and IL-6. 
These studies suggest the anti-infammatory activity of CS, unlike its absorption, does 
not systematically depend on any physicochemical parameters.  
 
Conclusions: Synthetic and natural CS samples with a range of molecular weights (7-
35 kDa) and sulfation patterns showed that the absorption of CS may be weakly 
correlated to % ΔDi-6S and is nearly independent of molecular weight. All the CS 
samples significantly inhibited expression of TNF-α  (at both low ~5 mg/ml and high ~15 
mg/ml concentrations) while the expression of IL-6 was inhibited by some of the CS 
samples at high concentration. We observed a weak correlation between the % 
reduction in TNF-α and MW and % ΔDi-total while no correlation seemed to exist 
between the IL-6 and physicochemical characteristics of CS. In conclusion, our studies 
provide a guiding tool in identifying the CS compounds that are most likely to be 
effective in vivo or in clinical studies. The in vitro screening strategies described in this 
article could help lower the expense incurred on the clinical trials by several folds by 
helping in sample pre-screening in terms of absorption and anti-inflammatory activity.  
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Figures and Figure Captions:  
 
 
 
Figure 1: The trends for Caco-2 cell effective permeability (Peff) as a function of 
molecular weight (a and b), %6S (c), and total sulfation (d).   
 
 
 
 
 
 
 
  
	  	  	  
Figure 2: The trends for moderately correlated TNF-a (MW and %total sulfation) from 
RAW 264.7 macrophages . The correlation coefficients for TNF-a on all 
physicochemical parameters are shown in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
Sample	  ID MW	  (kDa) %ΔDi-­‐0s %ΔDi-­‐4s %ΔDi-­‐6s 
A 7 6.91 66.61 26.49 
B 8 7.36 0 92.64 
C 21 9.06 64.21 26.73 
D 20 9.44 63.73 26.83 
E 31 10.14 68.84 21.01 
F 31 8.56 75.58 15.87 
G 35 11.11 0 88.89 
H 35 10.56 0 89.5 
 
Table 1: Molecular weight and the content of unsulfated, chondroitin-4-sulfate, and 
chondroitin-6-sulfate, determined using HPSEC and HPLC measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Pearson correlation coefficients R2 for % reduction in TNF-a, IL-6 and various 
physicochemical properties at two different concentrations of CS. 
 
 
  
